Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Capital Employed (ROCE) | 20.5% | (13.2%) | (18.6%) | (14.2%) | (14.9%) | (11.3%) | (11.4%) | (20.9%) | 55.0% | 20.3% | 13.8% | 16.4% | 16.5% | 17.4% | 26.7% | 16.2% | 24.0% | 42.4% | 17.8% | 13.8% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Return on Capital Employed (ROCE) is 11.1%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Capital Employed (ROCE) for Regeneron Pharmaceuticals, Inc. have been 21.6% over the past three years, and 22.0% over the past five years.
As of today, Regeneron Pharmaceuticals, Inc.'s Return on Capital Employed (ROCE) is 11.1%, which is higher than industry median of (50.6%). It indicates that Regeneron Pharmaceuticals, Inc.'s Return on Capital Employed (ROCE) is Good.